Hyderabad-based drug discovery research and development company GVK Biosciences (GVK Bio) has entered into a drug discovery alliance with US-based Moulder Center for Drug Discovery Research at Temple University in Philadelphia.
As part of the multi-year collaboration, GVK Bio will be responsible for the target validation, lead identification and lead optimisation of small molecules in selected therapeutic areas, including cardiovascular, metabolic and central nervous system disorders, a release said.
The Moulder Center is stated to be used for both internal research within Temple University and for external collaborations with pharmaceutical and biotech companies and other universities.
“This collaboration with Temple University is among several academic collaborations GVK Bio has with leading research institutions,” GVK Bio’s CEO, Manni Kantipudi, said.
Moulder Center director Magid Abou-Gharbia said the business model reflected the increasing trend of collaborations between academic centres of excellence and pharmaceutical companies to discover new drugs.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
